Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

20 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Addition of either lonidamine or granulocyte colony-stimulating factor does not improve survival in early breast cancer patients treated with high-dose epirubicin and cyclophosphamide.
Papaldo P, Lopez M, Cortesi E, Cammilluzzi E, Antimi M, Terzoli E, Lepidini G, Vici P, Barone C, Ferretti G, Di Cosimo S, Nistico C, Carlini P, Conti F, Di Lauro L, Botti C, Vitucci C, Fabi A, Giannarelli D, Marolla P. Papaldo P, et al. Among authors: marolla p. J Clin Oncol. 2003 Sep 15;21(18):3462-8. doi: 10.1200/JCO.2003.03.034. J Clin Oncol. 2003. PMID: 12972521 Clinical Trial.
Impact of five prophylactic filgrastim schedules on hematologic toxicity in early breast cancer patients treated with epirubicin and cyclophosphamide.
Papaldo P, Lopez M, Marolla P, Cortesi E, Antimi M, Terzoli E, Vici P, Barone C, Ferretti G, Di Cosimo S, Carlini P, Nisticò C, Conti F, Di Lauro L, Botti C, Di Filippo F, Fabi A, Giannarelli D, Calabresi F. Papaldo P, et al. Among authors: marolla p. J Clin Oncol. 2005 Oct 1;23(28):6908-18. doi: 10.1200/JCO.2005.03.099. Epub 2005 Aug 29. J Clin Oncol. 2005. PMID: 16129844 Clinical Trial.
Does granulocyte colony-stimulating factor worsen anemia in early breast cancer patients treated with epirubicin and cyclophosphamide?
Papaldo P, Ferretti G, Di Cosimo S, Giannarelli D, Marolla P, Lopez M, Cortesi E, Antimi M, Terzoli E, Carlini P, Vici P, Botti C, Di Lauro L, Naso G, Nisticò C, Mottolese M, Di Filippo F, Ruggeri EM, Ceribelli A, Cognetti F. Papaldo P, et al. Among authors: marolla p. J Clin Oncol. 2006 Jul 1;24(19):3048-55. doi: 10.1200/JCO.2005.02.9488. Epub 2006 Jun 12. J Clin Oncol. 2006. PMID: 16769988 Clinical Trial.
Fluorouracil, doxorubicin, and cyclophosphamide versus fluorouracil, doxorubicin, and cyclophosphamide plus lonidamine for the treatment of advanced breast cancer: a multicentric randomized clinical study.
Calabresi F, Di Lauro L, Marolla P, Curcio CG, Paoletti G, Calabró A, Giannarelli D, Ballatore P, Foggi CM, Di Palma M, et al. Calabresi F, et al. Among authors: marolla p. Semin Oncol. 1991 Apr;18(2 Suppl 4):66-72. Semin Oncol. 1991. PMID: 2031201 Clinical Trial.
Plasmacytoma of the thyroid gland.
Lopez M, Di Lauro L, Marolla P, Madonna V. Lopez M, et al. Among authors: marolla p. Clin Oncol. 1983 Mar;9(1):61-6. Clin Oncol. 1983. PMID: 6851309
A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience.
Vici P, Pizzuti L, Michelotti A, Sperduti I, Natoli C, Mentuccia L, Di Lauro L, Sergi D, Marchetti P, Santini D, Magnolfi E, Iezzi L, Moscetti L, Fabbri A, Cassano A, Grassadonia A, Omarini C, Piacentini F, Botticelli A, Bertolini I, Scinto AF, Zampa G, Mauri M, D'Onofrio L, Sini V, Barba M, Maugeri-Saccà M, Rossi E, Landucci E, Tomao S, Alberti AM, Giotta F, Ficorella C, Adamo V, Russo A, Lorusso V, Cannita K, Barni S, Laudadio L, Greco F, Garrone O, Della Giulia M, Marolla P, Sanguineti G, Di Cocco B, Ciliberto G, De Maria R, Gamucci T. Vici P, et al. Among authors: marolla p. Oncotarget. 2017 May 25;8(34):56921-56931. doi: 10.18632/oncotarget.18176. eCollection 2017 Aug 22. Oncotarget. 2017. PMID: 28915642 Free PMC article.
20 results